Celsion Announces Presentation Highlighting Phase III OPTIMA Study at the Asia-Pacific Primary Liver Cancer Expert Meeting
11 juil. 2016 08h00 HE | Celsion Corporation
LAWRENCEVILLE, N.J., July 11, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that its ongoing Phase III OPTIMA trial evaluating ThermoDox® in primary liver cancer,...
Celsion Corporation to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
07 juil. 2016 08h00 HE | Celsion Corporation
LAWRENCEVILLE, N.J., July 07, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that Michael H. Tardugno, chairman, president and chief executive officer, will present at...
Celsion Announces the Potentially Curative Approach to Treatment of Primary Liver Cancer - The Focus of Hepatic Oncology Peer-Reviewed Article
21 juin 2016 08h00 HE | Celsion Corporation
Ongoing Phase III Trial to Confirm Hypothesis That The Combination of Standardized Radio Frequency Ablation (sRFA) Plus Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) May Substantially Increase...
Celsion Corporation Announces $6 Million Registered Direct Offering
13 juin 2016 14h03 HE | Celsion Corporation
LAWRENCEVILLE, N.J., June 13, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (the “Company”) (NASDAQ:CLSN) today announced that it has entered into a definitive agreement with a single healthcare...